Stockscreener 앱 받기
19.99
0.99%
-0.20
시장 영업 전:
20.88
0.89
+4.45%
전일 마감가:
$20.19
열려 있는:
$20.19
하루 거래량:
503.30K
Relative Volume:
0.85
시가총액:
$834.63M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-0.79%
1개월 성능:
+42.48%
6개월 성능:
+360.60%
1년 성능:
+360.60%
1일 변동 폭
$19.31
$20.25
1주일 범위
$19.31
$21.50
52주 변동 폭
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
명칭
Bioage Labs Inc
전화
510-806-1445
주소
5885 HOLLIS STREET, EMERYVILLE
Compare BIOA vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
19.99 | 842.98M | 0 | 0 | 0 | 0.00 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 개시 | Piper Sandler | Overweight |
| 2025-12-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-02-28 | 개시 | William Blair | Mkt Perform |
| 2024-12-10 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-09 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-10-21 | 개시 | Citigroup | Buy |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-21 | 개시 | Morgan Stanley | Overweight |
모두보기
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
BioAge Labs (NASDAQ:BIOA) Trading Down 5.6%Here's What Happened - MarketBeat
S P Trends: Whats the beta of BioAge Labs Inc stockShare Buyback & Consistent Return Investment Signals - baoquankhu1.vn
BioAge Labs (BIOA) Price Target Increased by 127.08% to 27.80 - Nasdaq
Morgan Stanley Boosts Price Target on BioAge Labs to $23 From $12, Keeps Equalweight Rating - marketscreener.com
BioAge Labs (NASDAQ:BIOA) Insider Sells $139,368.75 in Stock - MarketBeat
BioAge Labs (NASDAQ:BIOA) Upgraded at Wall Street Zen - MarketBeat
BioAge Labs (NASDAQ:BIOA) Trading 8% HigherHere's Why - MarketBeat
BioAge Labs, Inc. (NASDAQ:BIOA) Short Interest Update - MarketBeat
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential - Pharma Voice
BioAge Labs Completes $115 Million Upsized Public Offering - Global Legal Chronicle
Piper Sandler Initiates Coverage of BioAge Labs (BIOA) with Overweight Recommendation - Nasdaq
Is BioAge Labs Inc.’s ROE strong enough2025 Price Targets & Free Safe Capital Growth Stock Tips - mfd.ru
BioAge Labs (NASDAQ:BIOA) Shares Gap UpShould You Buy? - MarketBeat
Piper Sandler Initiates BioAge Labs at Overweight With $73 Price Target - marketscreener.com
BioAge Labs: De-Risked NLRP3 Program and 2026 Clinical Catalysts Underpin Overweight/Buy Rating - TipRanks
BioAge Labs stock initiated with Overweight rating by Piper Sandler - Investing.com UK
BioAge Labs (NASDAQ:BIOA) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Fenwick Represents BioAge Labs in $115M Upsized Public Offering - fenwick.com
Aug PreEarnings: Should you avoid PepsiCo Inc stock right nowEarnings Summary Report & Consistent Profit Trading Strategies - baoquankhu1.vn
BioAge Labs prices upsized stock offering of $115M - MSN
BioAge Labs (NASDAQ:BIOA) Stock Price Down 4.1%Here's What Happened - MarketBeat
BioAge Labs Announces Upsized Public Equity Offering - TipRanks
BioAge Labs Signs Underwriting Agreement With Goldman Sachs, Piper Sandler and Citigroup Global Markets - TradingView
BioAge Labs expands into DME clinical program for oral inhibitor asset - Eyes On Eyecare
BioAge Labs: Early-Stage NLRP3 Opportunity in Ophthalmology and Cardiometabolic Disease Warrants Neutral ‘Hold’ Amid Long Clinical Timelines - TipRanks
BioAge Labs edges down after stock sale hiked to $115 mln - TradingView
BioAge Labs (BIOA) Prices Upsized Public Offering at $19.50, Targeting $115M - Intellectia AI
BioAge Labs prices upsized public offering at $19.50 per share By Investing.com - Investing.com Nigeria
Fund Flows: Is BioAge Labs Inc in accumulation or distribution phase2025 Market WrapUp & Reliable Price Action Trade Plans - baoquankhu1.vn
BioAge Labs prices upsized public offering at $19.50 per share - Investing.com
BioAge Announces Pricing of Upsized $115.0 Million Public Offering - Yahoo Finance
Metabolic disease biotech BioAge raises $115M in stock sale - Stock Titan
Dow Update: Will SPDR Gold Trust benefit from rate cutsTrade Ideas & Pattern Based Trade Signal System - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Shares Gap DownTime to Sell? - MarketBeat
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
BioAge Announces Proposed $75 Mln Public Offering; Expands BGE-102 Development Into Ophthalmology - Nasdaq
BioAge Labs announces $75 million public stock offering By Investing.com - Investing.com Nigeria
BioAge expands BGE-102 program to diabetic macular edema By Investing.com - Investing.com India
BioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating - TipRanks
BioAge stock falls after announcing $75 million public offering By Investing.com - Investing.com South Africa
BioAge Labs announces $75 million public stock offering - Investing.com
BioAge Announces Proposed Public Offering - manilatimes.net
BioAge expanding indication for NLRP3 inhibitor BGE-102 into DME - The Pharma Letter
BioAge expands BGE-102 program to diabetic macular edema - Investing.com
BioAge Labs advances BGE-102 into ophthalmology clinical trials - TipRanks
BioAge Labs, Inc. Expands Indication for BGE-102 to Diabetic Macular Edema - TradingView — Track All Markets
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 - The Manila Times
Pill for diabetic eye swelling: BioAge tests oral alternative to eye injections - stocktitan.net
Bioage Labs Inc (BIOA) 재무 분석
Bioage Labs Inc (BIOA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.21%
0.15%
자본화:
|
볼륨(24시간):